Clinical Trials Browser

Adenocarcinoma Of Esophagus, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Colitis, Ulcerative, Colonic Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma

NCT03711058 2025-09-16

Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer

Phase 1/2 Completed

48 enrolled 16 charts

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Spinocerebellar Degenerations

NCT06490536 2025-08-29

The Sagittarius Trial

Phase 3 Recruiting

700 enrolled

Gastrointestinal

Colonic Neoplasms

NCT03350126 2025-07-23

NIPICOL

Phase 2 Active not recruiting

57 enrolled

Gastrointestinal

Colonic Neoplasms, Microsatellite Instability

NCT03442569 2025-07-01

PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC

Phase 2 Completed

56 enrolled 13 charts

Gastrointestinal

Colonic Neoplasms

NCT03642067 2025-06-15

Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer

Phase 2 Completed

59 enrolled 11 charts

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Spinocerebellar Degenerations, Colorectal Neoplasms

NCT03667716 2025-01-17

COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.

Phase 1 Completed

121 enrolled

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Colonic Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03631641 2024-07-01

Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy

Phase 2 Terminated

3 enrolled 5 charts

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis

NCT03993626 2019-06-21

CAROSELL

Phase 1/2 Unknown

55 enrolled

Gastrointestinal

Colonic Neoplasms

Clinical Trials

NICHE

Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer

Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer

Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer

SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial

Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer

Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer

Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer

PSI-Immune

Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer

The Sagittarius Trial

NIPICOL

PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC

Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer

COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.

Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy

CAROSELL